Legal Representation
Attorney
Ashly I. Boesche
USPTO Deadlines
Next Deadline
210 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
February 25, 2026
Extension Available
Until February 25, 2026
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 14, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 13, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 13, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 13, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 25, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 31, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 31, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 25, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 6, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 6, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 6, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 2, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 2, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 2, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 9, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 9, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 4, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 2, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 26, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical preparations for scientific purposes; chemical preparations for supplementation of fibrinogen not for medical or veterinary use; Biological agents for industrial and scientific purposes made from human blood, blood plasma or blood serum, namely, proteins and protein preparations in the nature of albumin, immune globulins and fibrinogen; Biological agents for industrial and scientific purposes, namely, blood-derived proteins in the nature of coagulation factors; Biological agents for commercial and industrial purposes, namely, blood-derived plasma and blood serum sample preparations
Class 005
Pharmaceutical, medical and veterinary preparations for the treatment congenital and acquired fibrinogen deficiency; blood substitutes and blood plasma substitutes for human use; blood serum and blood serum proteins made from human blood for medical use; coagulants made from human blood plasma for medical use; fibrinogen, fibrinogen made from human blood plasma for medical use; pharmaceutical preparations for use in treating blood diseases and for use in medical transplants and oncology; veterinary preparations for treating blood diseases; pharmaceutical preparations for use in blood coagulation
Classification
International Classes
001
005